Telix Pharmaceuticals Limited (ASX: TLX) has announced a strategic agreement to partner with ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaft mbH (ABX-CRO) and Quantinm AB to commercialize the QDOSE® dosimetry software platform. This collaboration aims to advance personalized treatment regimens by integrating QDOSE® into Telix's therapeutic radiopharmaceutical programs and clinical collaborations.

QDOSE® is a validated software platform designed to estimate patient-specific dosimetry for both therapeutic and diagnostic radiopharmaceuticals. By leveraging QDOSE®, Telix seeks to optimize treatment response while minimizing adverse effects on healthy tissues, ultimately improving clinical outcomes. The platform supports dosimetry calculations using various imaging techniques and has received regulatory clearances from both the FDA and CE marking for clinical use in the EU.

Dr. Christian Behrenbruch, Managing Director and Group CEO of Telix, emphasized the growing importance of personalized dosimetry in cancer care and regulatory expectations regarding dosimetry analysis. He expressed confidence in positioning QDOSE® as an industry standard in dosimetry analysis.

Financial details of the partnership include non-material up-front transaction consideration from Telix, with undisclosed product royalties and fees on future product sales.